HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sunitinib effective for rare thymus cancer.

Abstract
In a phase II trial, the tyrosine kinase inhibitor sunitinib was effective in previously treated patients with thymic carcinoma, offering the first viable second-line treatment option for patients with this rare and aggressive form of thymus cancer.
Authors
JournalCancer discovery (Cancer Discov) Vol. 5 Issue 4 Pg. 340 (Apr 2015) ISSN: 2159-8290 [Electronic] United States
PMID25680712 (Publication Type: News)
Copyright©2015 American Association for Cancer Research.
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Clinical Trials, Phase II as Topic
  • Humans
  • Indoles (therapeutic use)
  • Pyrroles (therapeutic use)
  • Sunitinib
  • Thymus Neoplasms (drug therapy, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: